Impact of Dexamethasone on Respiratory Sequelae in the Follow-Up of Hospitalized Patients with Sars-Cov-2 Pneumonia
Patients treated with dexamethasone showed improved post-COVID respiratory outcomes, including less dyspnea, better lung function, and fewer signs of fibrosis. These findings suggest that dexamethasone is associated with improved outcomes after severe COVID-19 pneumonia.
Authors
- María Florencia Pilia (ORCID: https://orcid.org/0009-0003-2880-4019)
- I Ojanguren
- David Espejo-Castellanos
- Christian Romero-Mesones
- Saliha Omari
- Maria Ramon
- Xavier Muñoz
- Maria-Jesus Cruz
Institutions
- Universitat Autònoma de Barcelona (ES)
- Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (ES)
Publication Details
- Journal
- Infection and Drug Resistance
- Published
- 2026-01-01
- DOI
- https://doi.org/10.2147/idr.s547449
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Fundació Institut de Recerca Hospital Universitari Vall d’Hebron
- Instituto de Salud Carlos III
- European Regional Development Fund